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Abstract
Introduction and hypothesis Bladder pain syndrome is a dif-
ficult condition to treat. The purpose of this systematic review
is to assess the effectiveness of various complementary thera-
pies available for treatment.
Methods This review was conducted in adherence with
Preferred Reporting Items for Systematic Reviews. Citations
were retrieved using a comprehensive database search (from
inception to July 2014: CINAHL, Cochrane, EMBASE,
Medline and SIGEL and grey literature). Studies that fulfilled
the inclusion criteria were selected. Eligibility consisted of
women with bladder pain syndrome, an intervention of
alternative/complementary therapies and an outcome of im-
provement of symptoms. Information regarding study charac-
teristics and primary outcomes was collated. The Cochrane
risk of bias scale was used to evaluate the quality of the studies
included.
Results A total of 1,454 citations were identified, 11 studies
fulfilled the inclusion criteria (4 randomised control trials
[RCTs] and 7 prospective studies). The key interventions
studied were acupuncture, relaxation therapy, physical thera-
py, hydrogen-rich therapy, diet and nitric oxide synthetase.
Conclusion Therapies with the potential for benefit in patients
with bladder pain syndrome are dietary management, acu-
puncture and physical therapy. These findings were obtained
from small studies and hence caution is advised. Robustly
designed multicentre RCTs on these complementary therapies
are needed to guide patients and clinicians.
Keywords Alternative or complementary therapies .
Myofascial physical therapies . Acupuncture . Bladder pain
syndrome
Introduction
The European Society for the Study of Interstitial Cystitis/
Bladder Pain Syndrome in 2008 defined bladder pain syn-
drome (BPS) as pelvic pain, pressure or discomfort perceived
to be related to the bladder, lasting for at least 6 months, and
accompanied by at least one other urinary symptom [1].
Urinary symptoms include the persistent urge to void or fre-
quency, in the absence of other identifiable causes. The
International Urogynaecological Association (IUGA) and
the International Continence Society (ICS) produced a joint
report on terminologies by Haylen et al. in 2010, defining
bladder pain as a Bcomplaint of supra pubic or retro-pubic
pressure, discomfort or pain, associated with the bladder, gen-
erally aggravated by bladder filling. The symptommay persist
or alleviate after voiding.^ [2]. An estimated 400,000 people
in the UK suffer from BPS, the majority being women [3].
There is no definitive evidence to support an autoimmune,
inflammatory, st ructural or infect ious aet iology.
Consequently, treating these patients is often challenging.
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The interest in complementary and alternative therapies
among patients is high and the number of effective treatments
available for BPS are few [4]. Complementary and alternative
therapies are an essential addition to the therapeutic armamen-
tarium and include dietary modification, bladder training, acu-
puncture and stress reduction [5]. In 1995, complementary and
alternative medicine (CAM) was defined by the National
Institutes of Health (NIH) Center for Complementary and
Alternative Medicine as, those treatments and healthcare mo-
dalities not widely taught or practised in medical schools or
hospitals, and not usually reimbursed by medical insurance
companies [6].
Our aim was to conduct a systematic review to evaluate
the effectiveness of complementary therapies in the treatment
of BPS.
Materials and methods
This review was planned, conducted and reported in adher-
ence with widely recommended methods [7]. No ethical ap-
proval was needed.
Identification of studies
The following bibliographic databases were searched, from
database inception to July 2014: CINAHL, Cochrane,
EMBASE, Medline and SIGEL. Search strategies consisted
of MeSH subheadings, text words and word variations for
the concepts of BPS and alternative/complementary thera-
pies. The basic search strategy was adapted to suit the data-
base being searched. Librarians at the Royal College of
Obstetricians and Gynaecologists (RCOG) performed the
database searches. The search terms utilised by the RCOG:
(Interstitial cystitis OR painful bladder syndrome OR blad-
der pain syndrome) AND Analgesia OR Pain relief OR Diet
OR caffeine OR citrus OR Alcohol OR Smoking OR nico-
tine OR tobacco OR Physical therapy OR massage OR cup-
ping OR exercise OR bladder training OR pelvic floor ex-
ercise OR Kegel exercise OR Stress management OR
Psychology OR CBT OR talking OR counselling OR fo-
rums OR support groups OR acupuncture OR L-arginine.
The search was restricted to Bhumans^ and Bfemales^.
Bibliographies of relevant primary articles were also
searched to identify any articles missed by the electronic
searches. The conference proceedings and abstracts of the
International Continence Society (2004–2014) and
International Urogynecological Association meetings
(2004–2014) were also searched. A comprehensive database
was constructed using Endnote X7.2 for Windows, released
30 September 2014; Mac release date: 30 September 2014
[8] to store all references identified. No language restrictions
were applied.
Study selection and data extraction
Studies were selected following a two-step process. Firstly,
the citations identified by the electronic bibliographic data-
base searches were screened, based on their titles and ab-
stracts. Full text papers of eligible abstracts were retrieved.
Once full text papers had been located, we determined wheth-
er they fulfilled our predetermined inclusion criteria:
Population: women with BPS or interstitial cystitis (IC).
Intervention: complementary or alternative therapies
Comparator: no treatment, another therapy
Outcome: improvement in bladder symptoms
Study designs: randomised controlled trial (RCT), cohort
studies, case control studies, case series
Exclusion criteria: pharmacological therapy, intravesical
therapy, hydrodistention, tibial nerve stimulation
Two reviewers (TV, RNR) independently assessed the full
text papers to determine if they met the above criteria. Any
disagreements regarding the eligibility of a paper were solved
through either consensus or arbitration by a third reviewer
(PML). Data from the manuscripts included were extracted
independently onto a pre-designed pro-forma. The literature
search was thorough and without language restrictions. The
grey literature was also searched and the data were extracted
by two reviewers independently to reduce bias.
Data were collated on study characteristics, including
methods of recruitment, patient characteristics, details of com-
plementary therapy, outcomes and results. We contacted pri-
mary authors via email for any further information/
clarification that was needed.
Methodological quality
The methodological quality of all the papers fulfilling the
inclusion criteria was assessed. Quality was defined as the
confidence that the study design, conduct and analysis
minimised bias in the estimation of effectiveness. Quality
was assessed using existing checklists and scales [9, 10].
The methodological quality of the RCTs included was
assessed using the Cochrane risk bias score [9]. The method-
ological quality of the non-RCTstudies included was assessed
using the Newcastle–Ottawa scale [10], where a non-
randomised study was considered to be of high quality if it
provided information on selection, comparability, exposure
and outcome of the study participants. The quality checklist
awards one star as a maximum for all items except compara-
bility, where a maximum of two stars can be awarded. The
scale was used to give a quantitative appraisal of overall qual-
ity of the non-randomised studies. The score ranged from 0 to
9, with a score of either 0 or 1 for each item.
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Data synthesis
We grouped studies according to their type of intervention and
the comparison. The comparisons were with no intervention,
with placebo or with another intervention. The outcome mea-
sures were based on the responses from questionnaires such as
the Visual Analogue Score (VAS) [11], the Interstitial Cystitis
Symptom Index (ICSI)/O’Sant Leary questionnaire [12], the
Interstitial Cystitis Problem Index (IPSI) [12] and the maxi-
mum voided volume (MVV) on the frequency volume chart.
Results
Out of the 1,454 citations identified by electronic literature
searches, 11 studies that fulfilled the inclusion criteria were
included in the systematic review (Fig. 1); 4 were randomized
controlled trials (RCTs) and 7 were prospective studies. Table 1
provides a summary of the characteristics of the studies includ-
ed. The mean age of the women ranged between 43 and
64 years. The criteria for the diagnosis of BPS varied in the
studies included. Some studies diagnosed BPS clinically based
on bladder pain scale, frequency and urgency. Other studies
confirmed PBS based on the cystoscopic and hydrodistention
findings. Because of the varied definitions utilised in last
5 years, we set the inclusion criteria for womenwith a diagnosis
of BPS to be based on one of the following definitions: Hanash
and Pool [13, 14],Messing and Stamey [15], the ICS [2] or NIH
criteria [16], or the ESSIC definition (Table 1) [1]. Outcomes
were documented as per the symptom-specific scores (VAS
score, ICSI and ICPI).
Tables 2 and 3 provide details of the methodological qual-
ity of the RCTs included. Table 4 summarises details of the
quality of the non-randomised studies included.
Total number of citaons idenﬁed through electronic 
searches (n=1454)
Citaons excluded aer screening tles/ 
abstracts (n=1425)
Arcles retrieved for detailed evaluaon (n=30)
Arcles excluded: n=19
-Incorrect populaon n=1
-Duplicates n=2
-No useable data n=10
-Not locatable n=6
Arcles included in the systemac review (n= 11)
Fig. 1 Flow process of the
review
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Acupuncture and relaxation therapy
Honjo et al. investigated the clinical impact of sacral acupunc-
ture on urinary sensory dysfunction on a cohort of 36 patients,
11 of whom had BPS (see Table 1). The treatment was repeat-
ed weekly for 4 weeks. At the end of treatment there was a
significant decrease in the 24-h frequency and VAS for pain
(p<0.001) [17]. However, the results for the BPS and overac-
tive bladder patients were presented together, preventing an
assessment of symptoms in patients with BPS alone.
Similarly, Staack et al. reported on a pilot study of seven IC
patients in which 3 months of weekly acupuncture treatment
with electric stimulation led to modest improvement in the
urinary frequency, voiding difficulty and abdominal/genital
pain [18]. Katayama et al. examined the effectiveness of acu-
puncture and moxibustion in 8 women with refractory BPS.
38 % of women showed improvement in symptoms after
3 months [19].
In a study conducted at the University of Tennessee, 20
patients with IC were hypnotised every 2 weeks for 2 months.
Outcomes measured were a reduction in the analgesic require-
ments, increase in sleep time and quality of life (QoL). The
majority of patients (95 %; 19 out of 20) were amenable to
hypnotherapy and subsequently experienced pain reduction.
Five patients reported a significant improvement (8–10 to 0–1
out of 10) on VAS and 85 % (n=17 out of 20) were able to
reduce their intake of analgesics by 25–50% [20]. Carrico et al.
conducted a pilot RCT in which more than 45 % of the treat-
ment group responded to Bguided imagery ,^ with amoderate or
marked improvement in the global response rates (Table 1). In
addition, the treatment group had a significant reduction in their
ICSI (p=0.006) and ICPI scores (p=0.004) [21].
Table 2 Risk of bias summary of the randomised control studies included
KEY:
+ indicates low risk of bias
- indicates high risk of bias
? unclear risk of bias
KEY:
+ indicates low risk of bias
- indicates high risk of bias
? unclear risk of bias
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Hydrogen-rich therapy
Matsumoto et al. conducted an RCT (30 women) of hydrogen-
rich water versus placebo water for 2 months. The authors
describe the process of the production of hydrogen-rich water.
This was produced by passage through a reverse osmosis, an
ion-exchange resin, and an ultrafiltration membrane.
Hydrogen-rich pure water was then produced from dissolving
hydrogen gas directly into pure water. To prevent the loss of
hydrogen, the water is sealed in aluminium pouches and stored
at room temperature. The study demonstrated no significant
differences between treatment and placebo (Table 1) [22].
Physical therapy
FitzGerald et al. conducted a multicentre RCT (n=81 women)
to determine the efficacy of myofascial physical therapy (MPT)
compared with global therapeutic massage (GTM) [23]. The
MPT group underwent connective tissue manipulation to all
body wall tissues of the abdominal wall, back, buttocks and
thighs that were clinically found to have connective tissue ab-
normalities to painful myofascial trigger points. Manipulation
was applied bilaterally with the patient in the prone and then
repeated in the supine position. This was performed until a
texture change was noted. Manual trigger point release tech-
niques were utilized to treat any noted trigger points or scars in
the anterior or posterior lower quadrants. In the MPT arm, the
therapists tailored the therapy to target patient needs.
Patients randomised to the GTM group received weekly
massages consisting of full-body Western massage for 1 h.
The therapist utilised techniques such as effleurage,
petrissage, friction, tapotement, vibration and kneading.
At the end of 12 weeks, the global response rate was 26 %
in the GTM group and 59 % in the MPT (p=0.0012) group.
Both groups reported improvement in secondary outcomes,
including pain, urgency, frequency and QoL [23].
Similarly Ervan et al. conducted a non-randomised study on
women with BPS. The physical therapy included connective
tissue mobilisation over the trunk, thighs, buttocks and the
release of trigger points, the resolution of adverse neural ten-
sion along the pudendal nerve, rehabilitation of the pelvic floor
and hip girdle musculature. ICSI scores fell from median range
of 12 before treatment to 6 post-therapy (p<0.001). The ICPI
scores decreased from 10 to 7 after therapy (p<0.001) [24].
Women with BPS tend to have hypertonic pelvic floor
muscle dysfunction. In these women, a combination of
transvaginal biofeedback and transcutaneous electric nerve
stimulation for more than 2 months has not been shown to
have a long-term beneficial effect [25].
L-arginine
Korting et al. undertook an RCT to investigate the efficacy of
L-arginine, which is a substrate for nitric oxide, in which there
were no differences between the groups according to
intention-to-treat analysis (Table 1) [26].
Ueda et al. in their prospective study administered citrates
to elevate the urine pH (Table 1). Urine alkalinisation was
shown to be effective at improving symptoms of BPS [27].
Sacral acupuncture is a safe and promising therapeutic al-
ternative, particularly in patients with PBS who have symp-
toms that do not respond to conventional treatments [17].
Acupuncture inhibits the transmission of pain and normalizes
sensory processing within the peripheral and/or central
Table 3 Risk of bias graph of the randomized control studies included
KEY:
+ indicates low risk of bias
- indicates high risk of bias
? unclear risk of bias
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nervous system. Patients with BPS display tension and ten-
derness of the pelvic floor musculature and connective tissue
restrictions of muscle, fascia and subcutaneous tissue of the
pelvic floor. Physical therapies, such as MPT, were found to
be beneficial in women with symptoms of BS and associated
pelvic floor tenderness [23].
Discussion
To date there has been a paucity of studies addressing the ef-
fectiveness of complementary therapies in BPS. Results obtain-
ed from the small-scale studies we reviewedmust be considered
with caution because of the number of participants. Moreover,
the definition of BPS in various studies is not uniform. Several
unanswered questions regarding complementary therapies exist
including, its applicability to all patients with BPS and the cost-
effectiveness of treatment. The majority of studies reviewed
undertook a limited period of follow-up prohibiting analysis
of the long-term efficacy of the treatment. Studies evaluating
the role of tibial nerve stimulation were excluded, as this has
been explored in a recent systematic review [28].
The studies included did not discuss details of adverse effects
of complementary therapies. However, in 2009 a group of CAM
researchers conducted a workshop to discuss the challenges and
safety issues of CAM. They found a low incidence of harmful/
serious side effects from CAM [29]. Prospective observational
studies have been conducted to evaluate the harmful effects of
acupuncture; it has been found to be relatively safe. The data
from 2.2 million treatment sessions found a risk of harmful
events to be 1 in 76,000 patients [30]. The most common side
effects noted with acupuncture were minor, e.g. bleeding or
haematoma.
Shorter et al. utilised a validated questionnaire (IC/nutrition
questionnaire) in a survey to detect whether food, beverages and
supplement affect bladder symptoms in patients with BPS [31].
Analysis of the scoring of individual comestible items revealed
that most bothersome consumables were caffeinated, carbonated
and alcoholic beverages, citrus fruits and juices, artificial sweet-
eners and spicy foods. These results were obtained from survey
rating and therefore further research and studies are required for
confirmation of the results of the surveys conducted. Relief of
symptoms was noted following ingestion of alkaline agents, e.g.
calcium glycerophosphate (Prelief®) or sodium bicarbonate
(baking soda). Interestingly, 75 % of respondents indicated that
they had allergies, including seasonal allergies, allergies to med-
ications, animals or foods. The survey conducted on female twins
(n=9,349) found that tea consumption was associated with an
increased risk of BPS (OR 1.74, 95%CI 1.24–2.44), although
coffee consumption was not (OR 1.1, 95%CI 0.84–1.45) [32].
Former and current smoking was associated with a higher risk of
BPS (OR 1.5, 95%CI 1.18–1.89 andOR1.49, 95%CI 1.16–1.92
respectively) [33].Ta
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In 2009, the Interstitial Cystitis Association (ICA) conduct-
ed an Internet-based survey of complementary therapies. A
total of 2,101 responded to the survey; 1,982 confirmed an
IC diagnosis. 84.2 % had tried complementary therapies and
55 % said that physicians had recommended complementary
therapies [4]. Therapies perceived to be helpful included die-
tary management, myofascial physical therapy, temperature-
related therapies, acupuncture, stress reduction and exercise.
Some supplements, such as calcium glycerophosphate
(Prelief), vitamin D, fish oil and probiotics, were also consid-
ered to be helpful. Calcium glycerophosphate appears to reduce
BPS symptoms in a patient whose symptoms are exacerbated
by particular foods [34]. Tettamanti et al. reported their findings
from a population-based study demonstrating that tea and
smoking were positively associated with BPS [33].
Many interstitial cystitis (IC) patients resort to non-
conventional therapies after the failure of conventional measures.
Unfortunately, little research on complementary and alternative
therapies in the treatment of IC exists [5] and this is confirmed by
our systematic review. Complementary and alternative medical
therapy for interstitial cystitis (IC) is multimodal and individ-
ualized. Patients should be advised about the lack of robust
evidence on complementary therapies and encouraged to par-
ticipate in on-going studies on various therapies related to
BPS [35].
In view of the dearth of robust evidence, there is a need for
adequately powered RCTs to assess the effectiveness of com-
plementary therapies in women with BPS. Studies could focus
on therapies demonstrating potential with the limited evidence
to date including: L-arginine, acupuncture, hypnotherapy and
dietary modifications.
Acknowledgements Dr Seema A. Tirlapur, specialist registrar from
Barts and the London School of Medicine and Dentistry, for giving us
the idea and for her help with the literature search.
Compliance with ethical standards
Funding None.
Conflicts of interest None.
Open Access This article is distributed under the terms of the Creative
Commons At t r ibut ion 4 .0 In te rna t ional License (h t tp : / /
creativecommons.org/licenses/by/4.0/), which permits unrestricted use,
distribution, and reproduction in any medium, provided you give appro-
priate credit to the original author(s) and the source, provide a link to the
Creative Commons license, and indicate if changes were made.
References
1. Van de Merwe JP, Nordling J, Bouchelouche P et al (2008)
Diagnostic criteria, classification, and nomenclature for painful
bladder syndrome/interstitial cystitis: an ESSIC proposal. Eur
Urol 53(1):60–67
2. Haylen BT, de Ridder D, Freeman RM, Swift SE, Berghmans B,
Lee J et al (2010) An International Urogynecological Association
(IUGA)/International Continence Society (ICS) joint report on the
terminology for female pelvic floor dysfunction. Neurourol Urodyn
29(1):4–20
3. The cystitis and overactive bladder foundation. Accessed 26 June
2015. Available from: http://www.cobfoundation.org/interstitial-
cystitispainful-bladder-syndrome
4. O'Hare PG 3rd, Hoffmann A, Allen P, Gordon B, Salin L,
Whitmore K (2013) Interstitial cystitis patients' use and rating of
complementary and alternative medicine therapies. Int Urogynecol
J 24(6):977–982
5. Whitmore KE (2002) Complementary and alternative therapies as
treatment approaches for interstitial cystitis. Rev Urol 4(Suppl 1):
S28–S35
6. Ernst E, Resch KL, Mills S, Hill R, Mitchell A,Willoughby M et al
(1995) Complementary medicine—a definition. Br J Gen Pract
45(398):506
7. Moher D, Liberati A, Tetzlaff J, Altman DG, Group P (2009)
Preferred reporting items for systematic reviews and meta-analyses:
the PRISMA statement. BMJ 339:b2535
8. Williamson I (2008) "EndNote", software for small business.
Windows and Vista programs to help you improve efficiency and
productivity. Productive Publications. Accessed 14 May 2012
9. Higgins JP, Altman DG, Gotzsche PC, Juni P, Moher D, Oxman
AD et al (2011) The Cochrane Collaboration's tool for assessing
risk of bias in randomised trials. BMJ 343:d5928
10. Deeks JJ, Dinnes J, D'Amico R, Sowden AJ, Sakarovitch C, Song F
et al (2003) Evaluating non-randomised intervention studies. Health
Technol Assess 7(27):iii–x, 1–173
11. Wewers ME, Lowe NK (1990) A critical review of visual analogue
scales in the measurement of clinical phenomena. Res Nurs Health
13(4):227–236
12. O'LearyMP, Sant GR, Fowler FJ Jr, Whitmore KE, Spolarich-Kroll
J (1997) The interstitial cystitis symptom index and problem index.
Urology 49 [5A Suppl]:58–63
13. Hanash KA, Pool TL (1969) Interstitial cystitis in men. J Urol
102(4):427–428
14. Hunner GL (1918) A rare type of bladder ulcer: further notes and a
report of 18 cases. JAMA J Am Med Assoc 70:208–212
15. Messing EM, Stamey TA (1978) Interstitial cystitis: early diagnosis,
pathology, and treatment. Urology 12(4):381–392
16. Wein AJ, Hanno P, Gillenwater JY (1990) Interstitial cystitis: an
introduction to the problem. In: Hanno PM, Staskin DR, Krane RJ,
Wein AJ (eds) Interstitial cystitis. Springer, London, pp 3–15
17. Honjo HUO, Kitakoji H, Ushijima S, Kawauchi A, NakaoM,Miki
T (2007) Sacral acupuncture normalized bladder sensory dysfunc-
tion of C-fiber in patients with overactive bladder and painful blad-
der syndrome. http://www.ics.org/Abstracts/Publish/45/000408.pdf
18. Staack A, Twiss C, Arboleda V et al (2010) Acupuncture for the
treatment of interstitial cystitis—a pilot study. Female Pelvic Med
Reconstr Surg 16(5):S163
19. Katayama Y, Nakahara K, Shitamura T, Mukai S, Wakeda H,
Yamashita Y et al (2013) Effectiveness of acupuncture and moxi-
bustion therapy for the treatment of refractory interstitial cystitis.
Hinyokika Kiyo Acta Urol Jpn 59(5):265–269
20. Doggweiler R (2006) Hypnotherapy as a complementary treatment
of interstitial cystitis/chronic pelvic pain syndrome. International
Continence Society http://www.ics.org/Abstracts/Publish/44/
000237.pdf
21. Carrico DJ, Peters KM, Diokno AC (2008) Guided imagery for
womenwith interstitial cystitis: results of a prospective, randomized
controlled pilot study. J Altern Complement Med 14(1):53–60
Int Urogynecol J
22. Matsumoto S, Ueda T, Kakizaki H (2013) Effect of supplementa-
tion with hydrogen-rich water in patients with interstitial cystitis/
painful bladder syndrome. Urology 81(2):226–230
23. FitzGerald MP, Payne CK, Lukacz ES, Yang CC, Peters KM, Chai
TC et al (2012) Randomized multicenter clinical trial of myofascial
physical therapy in women with interstitial cystitis/painful bladder
syndrome and pelvic floor tenderness. J Urol 187(6):2113–2118
24. Ervan K, Arcilla G, Fortman C, Dillavou H, Fortman C, Kotarinos
E, FitzGerald MP, Kotarinos R (2006) Physical therapy can reduce
symptoms of painful bladder syndrome. Loyola UniversityMedical
Center, Chicago
25. Lee MH, Chen WC, Lee SP, Chen YC, Liu WB et al (2012)
Combination of pelvic floor biofeedback with electric stimulation
can improve chronic pelvic pain, lower urinary tract symptoms and
sexual dysfunction in patients with interstitial cystitis/bladder pain
syndrome (IC/BPS)—1 year follow up. International Continence
Society http://www.ics.org/Abstracts/Publish/134/000731.pdf
26. Korting GE, Smith SD, Wheeler MA, Weiss RM, Foster HE Jr
(1999) A randomized double-blind trial of oral L-arginine for treat-
ment of interstitial cystitis. J Urol 161(2):558–565
27. Ueda T, Yoshida T, Tanoue H, Ito M, Tamaki M, Ito Y et al (2014)
Urine alkalization improves the problems of pain and sleep in hy-
persensitive bladder syndrome. Int J Urol 21(5):512–517
28. Tirlapur SA, Vlismas A, Ball E, Khan KS (2013) Nerve stimulation
for chronic pelvic pain and bladder pain syndrome: a systematic
review. Acta Obstet Gynecol Scand 92(8):881–887
29. White A, Boon H, Alraek T, Lewith G et al (2014) Reducing the
risk of complementary and alternative medicine (CAM): challenges
and priorities. Eur J Intern Med 6(4):404–408
30. Witt CM, Pach D, Brinkhaus B, Wruck K, Tag B, Mank S et al
(2009) Safety of acupuncture: results of a prospective observational
study with 229,230 patients and introduction of a medical informa-
tion and consent form. Forsch Komplementmed 16(2):91–97
31. Shorter B, Lesser M, Moldwin RM, Kushner L (2007) Effect of
comestibles on symptoms of interstitial cystitis. J Urol 178(1):145–
152
32. Lichtenstein P, Sullivan PF, Cnattingius S, Gatz M, Johansson S,
Carlstrom E et al (2006) The Swedish Twin Registry in the third
millennium: an update. Twin Res Hum Genet 9(6):875–882
33. Tettamanti G, Nyman-Iliadou A, Pedersen NL, Bellocco R,Milsom
I, Altman D (2011) Influence of smoking, coffee, and tea consump-
tion on bladder pain syndrome in female twins. Urology 77(6):
1313–1317
34. Bologna RA, Gomelsky A, Lukban JC, Tu LM, Holzberg AS,
Whitmore KE (2001) The efficacy of calcium glycerophosphate
in the prevention of food-related flares in interstitial cystitis.
Urology 57 [6 Suppl 1]:119–120
35. Nickel JC, Jain P, Shore N, Anderson J, Giesing D, Lee H et al
(2012) Continuous intravesical lidocaine treatment for interstitial
cystitis/bladder pain syndrome: safety and efficacy of a new drug
delivery device. Sci Transl Med 4(143):143ra00
Int Urogynecol J
